Stämm Biotech
Juan Martín Cabaleiro has been working in various roles since 2009. Juan Martín began their career as an Investigador Independiente CIC at CONICET in 2009. In 2015, they became a Profesor Adjunto at the Facultad de Ingeniería de la UBA. In 2019, they took on the roles of Chief Technology Officer at Stämm Biotech and Conicet Microfluidics Consultant - Under S.T.A.N. contract between Conicet and Y-TEC. In 2020, they became a Conicet Microfluidics Consultant - Under S.T.A.N. contract between Conicet and CASPR BIOTECH.
Juan Martín Cabaleiro completed their Ingeniero degree in Mechanical Engineering from the University of Buenos Aires between 1997 and 2004. Juan Martín then pursued their Doctor of Philosophy - PhD in Fluid Dynamics and Electrical Engineering at the Université de Poitiers between 2004 and 2007.
This person is not in any offices
Stämm Biotech
Stämm is a biotechnology company dedicated to making biomanufacturing easy, scalable, and repeatable. We have developed the first methodology for continuous industrial production of biologics and cell therapies leveraging microfluidics and 3D printing. In 2020, the total volume of anthropogenic mass matched the total amount of biomass globally, which means it matched everything that is alive on the planet. We can only expect that this number keeps increasing since it's key to solving humanity's systemic challenges. But we have to make sure that conquering the great challenges of humanity doesn’t extinguish the planet’s capacity to sustain life. The current way of biomanufacturing has provided humanity with innumerable solutions. Bioprocessing is the most efficient way to align human advancement with a thriving nature. In order to prevent nature from perishing, we aim to put it at the center of all human activities by incorporating its knowledge system within the process of achieving humanity's prosperity. Founded in 2016, Stämm mimics nature’s use of laminar flow to down-size a whole biotech facility into an all-in-one, plug & play desktop unit. Our focus is to decentralize bioprocesses and democratize access to biotechnology products, thus freeing our partners to focus on the disruptive discoveries that make an impact on people’s life.